Healthcare Professionals

A Widely Adopted Molecular Test for Metastatic Patients with Poorly Differentiated Carcinomas and Cancer of Unknown Primary

CancerTYPE ID® is a molecular cancer classifier that helps identify the site of origin for cancers with indeterminate, uncertain, or differential diagnoses. The test uses real-time RT-PCR to measure the expression of 92 genes in the patient’s tumor and classifies the tumor by matching the gene expression pattern of the patient’s tumor to a database of known tumor types and subtypes, encompassing 50 tumor types.
What is CancerTYPE ID?
What Patients Qualify?
*NeoTYPE Cancer Profiles are performed and billed separately by our contracted reference laboratory, NeoGenomics Laboratories, Inc.

CancerTYPE ID Intended Use and Limitations

CancerTYPE ID is indicated for use in tumor specimens from patients diagnosed with malignant disease and is intended to aid in the classification of the tissue of origin and tumor subtype in conjunction with standard clinical and pathological assessment by a qualified physician. CancerTYPE ID is not intended to predict patient survival benefit, treatment efficacy or to distinguish between benign versus malignant lesions. Tumor types not included in the CancerTYPE ID reference database may exhibit RNA expression patterns that are similar to RNA expression patterns within the reference database. This test was developed and performance characteristics have been determined by Biotheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 as qualified to perform high-complexity clinical laboratory testing.